Introduction {#s0005}
============

Cancer of the renal pelvis and kidney is the second most common type of genitourinary malignancy in China, with an approximated 66,800 new cases and 23,400 mortality that occurred in 2015 [@bb0005]. For adults, renal cell carcinoma (RCC) accounts for a large proportion of kidney cancers. During the past few decades, the extensive use of cross-sectional imaging has resulted in the increasing number of patients presenting with low-stage disease. For most localized RCCs, surgery is the most reliable treatment modality, which can achieve satisfactory oncologic control [@bb0010]. However, RCC has a natural tendency of enlarging from the kidney along its route of venous drainage, which was identified in 4% to 10% of RCC patients [@bb0015]. These patients were classified as T3 according to TNM system of the 2010 American Joint Committee on Cancer [@bb0020]. Radical nephrectomy combining thrombectomy is currently the only potential cure for cases that have nonmetastatic RCC involving venous tumor thrombus (VTT) [@bb0025]. For these patients, although full surgical resection is performed, the risk of tumor recurrence can be nearly 50% in 3 years [@bb0030]. Therefore, surgery alone may not be sufficient for patients with nonmetastatic RCC and VTT.

Previous trials of postoperative adjuvant interleukin-2/interferon, chemotherapy, or hormonal therapy in patients with resected RCC at high risk for recurrence have all proven to be negative [@bb0035]. Small molecule agents targeting vascular endothelial growth factor pathway (sorafenib and sunitinib) can prolong the time to progression for patients with advanced RCC [@bb0040], [@bb0045]. Based on these facts, it seems to be meaningful to apply antiangiogenic agents for high-risk kidney cancer in the postoperative adjuvant setting. In two published randomized controlled studies, sunitinib was given for 1 year and compared to placebo in localized RCC cases at high risk for tumor recurrence after nephrectomy. Although one study demonstrated that 1 year of sunitinib therapy resulted in a 1.2-year longer time before the disease recurred, the other study did not show a survival benefit [@bb0050], [@bb0055]. This study is the first prospective cohort study to examine the role of postoperative adjuvant therapy (sorafenib or sunitinib) in nonmetastatic RCC patients with VTT.

Materials and Methods {#s0010}
=====================

Patient {#s0015}
-------

Eligible patients were older than 18 years and had histologically and clinically confirmed non--clear cell or clear cell RCC with VTT within 12 weeks of surgical resection of the primary mass and tumor thrombus. Other eligibility criteria included absence of macroscopic residual or metastatic disease after surgery, no previous systemic treatment, a good Eastern Cooperative Oncology Group performance status (0 or 1), and sufficient liver and bone marrow function. A creatinine clearance ≥40 ml/min for renal function was required. Exclusion criteria included bilateral RCC, hereditary or familial RCC, known HIV infection, uncontrolled hypertension, a major cardiovascular event or disease within 12 months before study entry, or preexisting thyroid disorder. Patients with carcinoma of the collecting ducts and renal medullary carcinoma were also excluded.

From March 2006 to January 2016, 147 patients undergoing radical nephrectomy and thrombectomy at our center who met the inclusion criteria were enrolled. All patients had the status of distant metastasis confirmed using imaging examinations and were staged in the light of the TNM system of the 2010 American Joint Committee on Cancer [@bb0020]. Thrombus level was classified according to the Mayo classification [@bb0060]. The present study was approved by Medical Ethics Committee of our hospital, and informed consent was acquired from each patient.

Study Design {#s0020}
------------

The trial was a single-institution, nonrandomized, prospective cohort study. Patients were classified to three groups according to postoperative treatment. The decision to receive sunitinib or sorafenib therapy was made mainly by the patients. Systemic treatment was initiated only if the patients recovered from the surgery with no complication. The treatment regimen was approximately 1 year of either sorafenib taken orally at 400 mg twice per day during a 4-week cycle or sunitinib taken orally at 50 mg per day for a 6-week cycle (4 weeks on treatment, 2 weeks off). The National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 was applied to evaluate the severity of treatment-related adverse events. Dose reductions were allowed for patients with grade 3 or higher drug-related toxic effects. Patients who experienced side effects that alleviated to below grade 2 within 4 weeks were escalated to full doses. Patients were removed from therapy if the dose reduction occurred more than twice for either agent. Therapy continued until disease recurrence, unacceptable toxicities, or patient withdrawal.

Assessment and Outcomes {#s0025}
-----------------------

Evaluation for toxic effects was performed every 6 weeks. Imaging (CT or MR) of the chest, abdomen, pelvis, and other applicable sites was performed every two cycles (interval of 2-3 months) during treatment for the initial year and every 6 months thereafter until disease recurrence. Diagnosis of recurrence was based on confirmed imaging or histologic findings. The patients who received systemic therapy after surgery were followed up for at least 12 months. All patients in the control group were imaged every 2 to 3 months for the initial year and then every 6 months thereafter.

The primary endpoint was disease-free survival (DFS), which was defined as the interval between inclusion and tumor recurrence, occurrence of a second tumor, or all-cause mortality. Patients who were alive without tumor recurrence were censored at the last follow-up. Secondary end points included overall survival (OS) and adverse effects.

Statistical Analysis {#s0030}
--------------------

All continuous data were shown as mean and standard deviation (SD) with a normal distribution, or as the median and interquartile range (IQR) when not normally distributed. For continuous data, the one-way analysis of variance or Kruskal-Wallis tests were applied to analyze the comparisons. For categorical variables, comparisons were performed by using the Pearson chi-square or Fisher exact test. We compared the three groups\' survival using the Kaplan-Meier method with log-rank test. Univariable and multivariable Cox proportional hazards analyses were also applied. Variables achieving *P* value \< .05 in the univariate analysis and therapy subgroup were incorporated in the multivariable model to determine independent predictive factors. All statistical analyses were performed with R software (version 3.3.1). Two-tailed tests were applied for all comparisons, and a *P* value \< .05 was deemed to be statistically significant.

Results {#s0035}
=======

The present study included 147 patients between March 2006 and January 2016; 27 patients received sorafenib, 17 patients received sunitinib, and 103 patients received no adjuvant therapy postoperatively. Baseline demographic and clinical features are presented in [Table 1](#t0005){ref-type="table"}. In line with the disease features of RCC, most patients included in the present study were male and had a good body condition. The three groups were well balanced in terms of age, body mass index (BMI), gender, performance status, medical history, American Society of Anesthesiologists (ASA) score, surgical approach, and tumor side and size. There were significant differences for level and length tumor thrombus, and pathological stage among the three groups (*P* \< .05 for all). More patients receiving adjuvant therapy had inferior vena cava tumor thrombus. After surgery, most patients were confirmed to have clear cell RCC. Positive lymph node was identified in five patients, four patients, and nine patients for sorafenib, sunitinib, and control. No significant differences were observed among the three groups with regard to histology, Fuhrman grade, tumor necrosis, sarcomatoid feature, perirenal fat invasion, sinus fat invasion, or collecting system invasion.Table 1Baseline CharacteristicsTable 1SorafenibSunitinibControl*P* ValueNo. of patients2717103Mean (SD) age, years56.2 (12.8)50.0 (7.2)57.3 (12.6).077Mean (SD) BMI25.1 (4.2)25.1 (3.0)24.5 (3.4).643Male, *n* (%)20 (74.1)15 (88.2)81 (78.6).529ECOG performance status, *n* (%).948 020 (74.1)13 (76.5)75 (72.8) 17 (25.9)4 (23.5)28 (27.2)Presenting symptoms, *n* (%)19 (70.4)11 (64.7)68 (66.0).898Diabetes mellitus, *n* (%)10 (37.0)3 (17.6)19 (18.4).104Hypertension, *n* (%)9 (33.3)4 (23.5)33 (32.0).757ASA score, *n* (%).283 1 + 222 (81.5)16 (94.1)80 (77.7) 3 + 45 (18.5)1 (5.9)23 (22.3)Tumor laterality, *n* (%).562 Left14 (51.9)6 (35.3)47 (45.6) Right13 (48.1)11 (64.7)56 (54.3)Surgical approach, *n* (%).821 Open15 (55.6)8 (47.1)51 (49.5) Minimally invasive12 (44.4)9 (52.9)52 (50.5)Thrombus level, *n* (%).002 Level 013 (48.1)3 (17.6)68 (66.0) Level I4 (14.8)6 (35.3)12 (11.7) Level II10 (37.0)8 (47.1)17 (16.5) Level III0 (0.0)0 (0.0)3 (2.9) Level IV0 (0.0)0 (0.0)3 (2.9)Median (IQR) thrombus length, cm3.5 (1.5-5.0)4.0 (3.0-6.0)2.0 (1.0-4.0).002Median (IQR) maximum tumor width, cm9.0 (6.0-10.0)8.0 (4.8-10.0)6.8 (5.0-9.0).124Pathological stage, *n* (%).001 T3a13 (48.1)3 (17.6)68 (66.0) T3b14 (51.9)14 (82.3)32 (31.0) T3c0 (0.0)0 (0.0)3 (2.9)Histological subtype, *n* (%).959 Clear cell24 (88.9)15 (88.2)87 (84.5) Papillary1 (3.7)0 (0.0)6 (5.8) Unclassified2 (7.4)2 (11.8)10 (9.7)Fuhrman grade, *n* (%).849 1 + 211 (40.7)7 (41.2)52 (50.5) 3 + 412 (44.4)8 (47.1)41 (39.8) Not determined4 (14.8)2 (11.8)10 (9.7)Tumor necrosis, *n* (%)15 (55.6)10 (58.8)43 (41.7).239Sarcomatoid feature, *n* (%)2 (7.4)1 (5.9)1 (1.0).080Perirenal fat invasion, *n* (%)5 (18.5)1 (5.9)12 (11.7).439Sinus fat invasion, *n* (%)0 (0.0)2 (11.8)7 (6.8).230Collecting system invasion, *n* (%)10 (37.0)8 (47.1)34 (33.0).522Positive lymph node, *n* (%)5 (18.5)4 (23.5)9 (8.7).107[^2]

At the last follow-up (February 2017), 33 patients have finished postoperative systemic therapy for at least 12 months, that is, roughly 9 cycles of sunitinib and 13 cycles of sorafenib. No patient was removed from the trial due to adverse events. Mean follow-up time for patients in the sorafenib, sunitinib, and control group was 39.4 ± 21.0, 36.6 ± 19.4, and 44.4 ± 28.7 months, respectively. Mean DFS was 24.1 months for sorafenib, 26.8 months for sunitinib, and 34.4 months for control. No significant difference was found for DFS among the three groups (*P* = .459; [Figure 1](#f0005){ref-type="fig"}*A*). Events were recorded for 16 patients in sorafenib group, 10 patients in sunitinib group, and 54 patients in control group. Mean OS was 35.5 months for sorafenib, 34.6 months for sunitinib, and 39.5 months for control. No significant difference was found for OS among the three groups (*P* = .871; [Figure 1](#f0005){ref-type="fig"}*B*). Events were recorded for 11 patients in sorafenib group, 5 patients in sunitinib group, and 40 patients in control group. After adjusting for potential confounding factors, results of multivariate analysis proved that postoperative adjuvant therapy was not an independent factor for predicting DFS and OS (*P* \> .05 for both; [Table 2](#t0010){ref-type="table"}).Figure 1DFS (A) and OS (B) for patients with nonmetastatic RCC and tumor thrombus.Figure 1Table 2Cox Proportional Hazards Regression for DFS and OS in Patients with RCC and Venous Tumor ThrombusTable 2DFSOSCharacteristicUnivariateMultivariateUnivariateMultivariate*P* ValueHR (95% CI)*P* Value*P* ValueHR (95% CI)*P* ValueAge.159.282BMI.127.0360.92 (0.83-1.02).126Sex (female vs male).585.990Presenting symptoms.255.062Diabetes.403.997Hypertension.886.394ASA score (3 + 4 vs 1 + 2).060.335Tumor laterality (right vs left).137.345Surgical approach (MI vs open).945.121Thrombus height Renal vein onlyRef.Ref. IVC below diaphragm.389.312 IVC above diaphragm.389.168Thrombus length.234.0321.09 (0.92-1.30).316Tumor width.0021.08 (1.00-1.17).059\<.0011.21 (1.08-1.36).001Histological subtype (ccRCC vs non-ccRCC).181.0050.43 (0.14-1.32).139Fuhrman grade (high vs low).0101.63 (1.00-2.66).049.0151.42 (0.75-2.71).281Tumor necrosis.187.292Sarcomatoid feature.294.381Perirenal fat invasion.874.936Sinus fat invasion.951.564Collecting system invasion.0051.83 (1.11-3.02).018.0121.95 (0.95-4.00).071Lymph node status (positive vs negative).916.607Therapy subgroup ControlRef.Ref.Ref.Ref. Sorafenib.2461.05 (0.57-1.96).875.7770.88 (0.41-1.88).736 Sunitinib.5060.84 (0.39-1.79).645.6950.40 (0.10-1.46).163[^3]

For patients with RCC and inferior vena cava tumor thrombus, mean DFS was 17.6 months for sorafenib, 21.9 months for sunitinib, and 32.0 months for control. No significant difference was found for DFS among the three groups (*P* = .380; [Figure 2](#f0010){ref-type="fig"}*A*). Events were recorded for 9 patients in sorafenib group, 8 patients in sunitinib group, and 18 patients in control group. Mean OS was 28.6 months for sorafenib, 30.9 months for sunitinib, and 38.6 months for control. No significant difference was found for OS among the three groups (*P* = .525; [Figure 2](#f0010){ref-type="fig"}*B*). Events were recorded for 7 patients in sorafenib group, 4 patients in sunitinib group, and 15 patients in control group. After adjusting for potential confounding factors, results of multivariate analysis proved that postoperative adjuvant therapy was not an independent factor for predicting DFS and OS (*P* \> .05 for both; [Table 3](#t0015){ref-type="table"}).Figure 2DFS (A) and OS (B) for patients with nonmetastatic RCC and inferior vena cava tumor thrombus.Figure 2Table 3Cox Proportional Hazards Regression for DFS and OS in Patients with RCC and Inferior Vena Cava Tumor ThrombusTable 3CharacteristicDFSOSUnivariateMultivariateUnivariateMultivariate*P* ValueHR (95% CI)*P* Value*P* ValueHR (95% CI)*P* ValueAge.602.647BMI.766.481Sex (female vs male).578.516Presenting symptoms.820.680Diabetes.115.261Hypertension.077.190ASA score (3 + 4 vs 1 + 2).104.121Tumor laterality (right vs left).0320.59 (0.27-1.30).189.0300.64 (0.25-1.67).360Surgical approach (MI vs open).476.085Thrombus height IVC below diaphragmRef.Ref. IVC above diaphragm.588.348Thrombus length.374.164Tumor width\<.0011.18 (1.05-1.32).007\<.0011.25 (1.08-1.44).002Histological subtype (ccRCC vs non-ccRCC).453.0190.25 (0.08-0.74).012Fuhrman grade (high vs low).675.427Tumor necrosis.854.905Sarcomatoid feature.464.649Perirenal fat invasion.566.897Sinus fat invasion.794.289Collecting system invasion.0291.42 (0.66-3.04).366.104Lymph node status (positive vs negative).471.686Therapy subgroup ControlRef.Ref.Ref.Ref. Sorafenib.1762.03 (0.87-4.73).103.3611.31 (0.51-3.33).578 Sunitinib.4851.20 (0.49-2.94).689.7060.70 (0.22-2.21).545

Sunitinib and sorafenib both were well tolerated, and most toxic effects were comparable [@bb0065]. The patient distribution with respect to toxicity is outlined in [Table 4](#t0020){ref-type="table"}. In the present study, the most common adverse events were hand-foot syndrome, diarrhea, fatigue, and neutropenia. Most of them were mild (grade 1 or 2) and can be easily managed. The frequency of adverse events did not differ significantly between sorafenib and sunitinib (*P* \> .05 for both). Adverse events that led to dose reductions included grade 3 diarrhea for four patients (two on sorafenib and two on sunitinib) and grade 3 neutropenia for three patients (two on sorafenib and one on sunitinib).Table 4Adverse Event in Sorafenib and Sunitinib GroupsTable 4SorafenibSunitinib*P* ValueHand-foot syndrome, *n* (%)17 (63.0)10 (58.8).784Diarrhea, *n* (%)15 (55.6)10 (58.8).831Fatigue, *n* (%)14 (51.9)9 (52.9).944Hypertension, *n* (%)9 (33.3)7 (41.2).598Rash, *n* (%)10 (37.0)5 (29.4).603Mucositis, *n* (%)8 (29.6)7 (41.2).431Pruritus, *n* (%)6 (22.2)3 (17.6).714Nausea, *n* (%)6 (22.2)6 (35.3).343Anorexia, *n* (%)4 (14.8)4 (23.5).690Hypothyroidism, *n* (%)4 (14.8)6 (35.3).114Alopecia, *n* (%)10 (37.0)6 (35.3).907Vomiting, *n* (%)4 (14.8)3 (17.4)1.000Neutropenia, *n* (%)9 (33.3)8 (47.1).363

Discussion {#s0040}
==========

Approximately 4% to 10% of RCC patients have lesions extending into the venous drainage system, generating VTT [@bb0070]. Most patients with no preoperative distant metastasis can be well managed with full surgical resection; however, the risk of tumor recurrence can be nearly 50% in 3 years [@bb0075]. Therefore, postoperative adjuvant therapy may be needed for these patients. Hence, this prospective cohort study was performed to compare survival time with adjuvant sunitinib or sorafenib versus control and ascertain the postoperative role of antiangiogenic agents in patients with nonmetastatic RCC and VTT.

In the present study, the mean time to tumor recurrence or mortality was similar between subjects who received postoperative sunitinib or sorafenib and those who did not receive any adjuvant therapy. It should be noted that there may be inherent selection bias and uncontrolled confounding factors because of the nonrandomized design. In the comparison of baseline demographic and clinical features, there were significant differences for level and length tumor thrombus, and pathological stage among the three groups. More patients receiving adjuvant therapy had inferior vena cava tumor thrombus. Hence, the further multivariate Cox analyses were performed. After adjusting for other variables, postoperative adjuvant therapy was not associated with DFS and OS. The subgroup analyses of RCC patients with inferior vena cava tumor thrombus were also performed. The results indicated that there was also no survival advantage for either drug. In spite of the positive role of VEGF-targeted therapy in cases with distant metastasis, our findings failed to identify any benefit from the two agents, sorafenib or sunitinib, versus control when taken in the postoperative adjuvant setting.

The results are comparable to those of preoperative molecular targeted therapies in patients undergoing radical nephrectomy and thrombectomy in which the effect of downsizing tumor of VEGF-targeted therapy in metastatic and localized RCC is not seen. For example, presurgical sunitinib was administered in 72 potential candidates for partial nephrectomy. Downsizing was observed in 65 (83%) masses, with partial responses in 15 (19%) patients. Most of them can be subsequently managed with partial nephrectomy with accompanying acceptable surgical morbidity and functional outcomes [@bb0080]. However, targeted molecular therapies had a limited clinical effect on RCC tumor thrombi and primitive tumor [@bb0085], [@bb0090]. After targeted molecular therapies, most patients had stable or upstaged thrombi. Regarding primary tumor, most patients had a stabilization or an increase in tumor size.

In the postoperative adjuvant setting, the concern has been proposed with regard to whether the micrometastases that probably lead to recurrent disease are of a blood supply that is as susceptible to the effect of VEGF-targeted therapy as is the case in macrometastases. Given the absent benefit from VEGF-targeted therapy, it may be rational to draw the conclusion that antiangiogenic therapy does not exert persistent antitumor effects in micrometastases. In particular, studies with experimental mouse renal tumor xenograft models found an incomprehensible result that targeted molecular agents improve metastatic neoplasm growth and reduce OS [@bb0095]. Results from several studies may explain this finding. Ebos et al. [@bb0100] investigated molecular plasma changes induced by sunitinib, including those both indirectly and directly targeted by agent. They found that many sunitinib-induced circulating proangiogenic factors rely on tumor and are associated with antitumor potency. Griffioen et al. [@bb0105] firstly described the angiostatic response in RCC at the tissue level upon treatment with VEGF-targeted therapy. Their results indicated that discontinuation of treatment with tyrosine kinase inhibitors leads to accelerated endothelial cell proliferation. Based on the histologic examination in a xenograft study, Hammers et al. [@bb0110] suggested that invertible epithelial to mesenchymal transition might be correlated with acquired tumor resistance to tyrosine kinase inhibitors in patients with clear cell RCC. Despite their unavoidable shortages, those mouse tumor xenograft models likely recognized a process that is related to the present human trial. Those possibly effective models may provide insight into the pathophysiology of VEGF-targeted therapy of RCC to guide prospective studies.

A number of trials have looked into whether adjuvant antiangiogenic agents can improve outcomes of high-risk RCC after nephrectomy. To date, results have been reported for two studies [@bb0050], [@bb0055]. The ASSURE trial was the first randomized phase 3 study. The recruited 1943 patients were randomized 1:1:1 to sorafenib, sunitinib, or placebo. No survival advantage was found for either drug, with not even a trend towards benefit in the treatment arm [@bb0050]. The second was a double-blind, placebo-controlled, randomized phase 3 trial (S-TRAC) involving 615 patients. Patients were randomized 1:1 to sunitinib or placebo. The DFS results for sunitinib were as follows: hazard ratio 0.76; 95% confidence interval (CI) 0.85-1.23; *P* = .03, which contradict ASSURE. On the basis of conflicting results from the two available studies, the European Association of Urology RCC guidelines panel does not recommend adjuvant therapy with sunitinib for patients with high-risk RCC after nephrectomy [@bb0115].

Several limitations of this study need to be acknowledged. First, the study was a single-center analysis with nonrandomized design. There may be inherent selection bias and uncontrolled confounding factors. Hence, the multivariable analyses were performed. Second, though we tried to follow up all patients until February 2017, the length of follow-up was still relative insufficient, especially for patients receiving targeted therapy. Third, this study had a small sample size of 147 patients, and the number of subjects in the adjuvant therapy groups was smaller than that of the control group.

Conclusion {#s0045}
==========

Despite these limitations, the present study initially investigates the use of sorafenib or sunitinib as postoperative adjuvant therapy in nonmetastatic RCC patients with VTT. Based on our results, these drugs should not be recommended for nonmetastatic RCC patients with VTT in the postoperative adjuvant setting.
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